West Pharmaceutical Services, Inc. WST NYSE

West Pharmaceutical Services, Inc. (WST) generated $251.1M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $76.1M, free cash flow was $175M.

Free cash flow margin was 21.7% of revenue. Cash conversion ratio was 1.9x, indicating earnings are backed by cash.

The company returned $15.8M in dividends and $200K in share buybacks to shareholders during the quarter.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (57/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (70/100) — Cash conversion ratio was 1.9x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 66/100 with 4/7 criteria passed.